Trial Profile
A Phase 1, Randomized, Open-label, Comparison of Heterologous Prime-Boost Vaccination Schedules of Tetravalent Dengue Virus Purified Inactivated Vaccine (PIV) and Tetravalent Dengue Virus Live Attenuated Vaccine (LAV) in Healthy Adults
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs TDENV LAV (Primary) ; TDENV PIV (Primary) ; Alum
- Indications Dengue
- Focus Adverse reactions
- 25 Mar 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 06 May 2020 Planned End Date changed from 1 Jun 2020 to 31 Dec 2020.
- 06 May 2020 Planned primary completion date changed from 1 Jan 2020 to 30 Jun 2020.